| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Revenue (note 11) | 5,289 | 2,211 | 2,621 | |
| Cost of sales | 1,358 | 593 | 768 | |
| Gross profit | 3,931 | 1,618 | 1,853 | |
| Research and development | 5,418 | 6,098 | 4,808 | |
| Selling, general and administrative | 7,426 | 9,326 | 8,211 | |
| Total operating expenses | 12,844 | 15,424 | 13,019 | |
| Operating loss | -8,913 | -13,806 | -11,166 | |
| Net finance (income) expense | 122 | 343 | 445 | |
| Net foreign exchange (gain) loss | 935 | -2,168 | 38 | |
| Total other (income) expenses | 1,057 | -1,825 | 483 | |
| Net loss before income taxes | -7,856 | -15,631 | -10,683 | |
| Income tax expense | 100 | 78 | 41 | |
| Deferred tax expense | 21 | -14 | - | |
| Total income tax expense | 121 | 64 | 41 | |
| Net loss attributed to shareholders for the period | -7,977 | -15,695 | -10,724 | |
| Foreign currency translation adjustment | -808 | 2,713 | 103 | |
| Net loss and other comprehensive loss for the period | -8,785 | -12,982 | -10,621 | |
| Earnings per share, basic | 0.26 | 0.52 | 0.36 | |
| Earnings per share, diluted | 0.26 | 0.52 | 0.36 | |
| Weighted average number of shares outstanding, basic | 30,104,497 | 30,053,142 | 30,041,735 | |
| Weighted average number of shares outstanding, diluted | 30,104,497 | 30,053,142 | 30,041,735 | |
Profound Medical Corp. (PROF)
Profound Medical Corp. (PROF)